Oxford BioDynamics - Director/PDMR Shareholding

Oxford Biodynamics

10/04/2025 16:10

RNS Number : 5753E

Oxford BioDynamics PLC

10 April 2025

 

                                                                      

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

 

PDMR Dealing

10 April 2025 - Oxford BioDynamics Plc (AIM: OBD) announces that it has received notice that Non-Executive Director Peter Presland has today purchased 3,398,553 ordinary shares of 0.1 pence each ("Ordinary Shares") at a price of 0.44p per share.

 

Following this transaction, Peter Presland is beneficially interested in a total of 3,398,553 Ordinary Shares, representing approximately 0.17% of the Company's current issued share capital.

The notification below, made in accordance with the requirements of UK Market Abuse Regulation, provides further details:

 

1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Peter Presland
2
Reason for the notification
a)
Position/status
Director/PDMR
b)
Initial notification/ Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Oxford BioDynamics Plc
b)
LEI
2138005Y1TK258O5U928
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares of 0.1 pence each
ISIN: GB00BD5H8572
b)
Nature of the transaction
Purchase of Ordinary Shares
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£0.0044
3,398,553
d)
Aggregated information
- Aggregated volume
- Price
n/a
e)
Date of the transaction
10 April 2025
f)
Place of the transaction
London Stock Exchange (XLON)

 

-Ends-

For further details please contact:

Oxford BioDynamics Plc
Iain Ross, Executive Chairman
Paul Stockdale, CFO
+44 (0)1865 518910
Shore Capital - Nominated Adviser and Broker
Advisory: Stephane Auton / Lucy Bowden
Broking: Fiona Conroy
+44 (0)20 7408 4090
WG Partners - Joint Broker
David Wilson / Claes Spång / Satheesh Nadarajah / Erland Sternby
+44 (0)20 3705 9330
OAK Securities - Joint Broker
Jerry Keen / Henry Clarke / Damion Carruel
+44 (0)20 3973 3678
Camarco - Financial PR
Marc Cohen / Tilly Butcher / Fergus Young
+44 (0)20 3757 4980
OBDFinancial@camarco.co.uk

 

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the EpiSwitch® PSE (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com,  X (@OxBioDynamics) or LinkedIn.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHFLFIESDIILIE